PARIS, April 7 Sanofi said it plans to
resubmit its application for its Lemtrada drug for the treatment
of relapsing forms of multiple sclerosis following "constructive
discussions" with the U.S. Food and Drug Administration.
The resubmission is expected in the second quarter and will
provide information to address issues previously raised by the
FDA in December, Sanofi said in a statement on Monday.
Sanofi's Genzyme unit in the United States had previously
announced its intention to appeal the FDA's response on
"In light of the planned resubmission, the company does not
expect to pursue an appeal at this time," Sanofi said.
(Reporting by James Regan; Editing by Blaise Robinson)